BCKDK and metabolic dysfunction-associated steatotic liver disease: A recent study described that ZFRs, which develop obesity and NAFLD, have reduced hepatic TG levels upon 1 week treatment with the BT2 compound (inhibitor of branched chain α-keto acid dehydrogenase kinase) (White et al., 2018).